Poor
Poorly Aligned
Patient Risk:
Moderate
Summary
The label supports Lipitor's HMG-CoA reductase mechanism and describes muscle-related adverse effects, but it does not substantiate the CoQ10-related causes, benefits, dosing, safety, interaction, or study claims. No direct contradiction with the supplied label is identified.
Category Scores
Accurate Statements
Lipitor (atorvastatin) lowers cholesterol by inhibiting HMG-CoA reductase.
Section 12.1 identifies Lipitor as a selective, competitive HMG-CoA reductase inhibitor and describes its effects on cholesterol measures.
Unsupported Statements
CoQ10 depletion contributes to statin-associated myalgia or fatigue, and CoQ10 supplementation restores levels or eases symptoms without affecting Lipitor efficacy.
The label reports muscle symptoms, including myalgia and muscle fatigue, but does not connect them to CoQ10 or discuss supplementation or its effect on Lipitor efficacy.
The cited 2018 meta-analysis and 2015 trial results, including pain reduction, no change in LDL lowering, and the claims about which patients benefit most.
The supplied label does not discuss these studies or provide evidence about CoQ10 benefits by CoQ10 level, symptom status, or Lipitor dose.
Statins lower blood CoQ10 by 20–40%, that decrease correlates with myopathy risk, and CoQ10 supports muscle energy production as an antioxidant.
Section 12.1 describes HMG-CoA reductase inhibition and mevalonate as a precursor of sterols, including cholesterol, but does not mention CoQ10 or these proposed effects.
CoQ10 at 100–200 mg/day normalizes levels, reduces creatine kinase elevations or pain scores, and does not reduce severe rhabdomyolysis risk.
The label discusses CPK, myopathy, and rhabdomyolysis in relation to Lipitor, but does not address CoQ10 or the cited supplementation findings.
The recommended CoQ10 starting dose is 100–200 mg daily; split doses with meals, use a plasma target above 2 mcg/mL, and expect benefits in 4–8 weeks.
The supplied label provides no CoQ10 dosage, administration, target level, or onset-of-benefit recommendations.
CoQ10 can be taken at any time relative to Lipitor because no interactions occur; it is safe at the stated doses and rarely causes mild gastrointestinal upset or slightly lowers blood pressure.
The label does not establish CoQ10's safety, adverse effects, or absence of an interaction with Lipitor. Its interaction section addresses other interacting agents, not CoQ10.
CoQ10 may interact with warfarin and INR should be monitored; ubiquinol has better bioavailability, especially in older adults.
The supplied label does not discuss warfarin or INR monitoring, CoQ10 forms, or bioavailability in older adults.
The American College of Cardiology and Mayo Clinic make the stated CoQ10 recommendations.
The supplied prescribing information does not describe recommendations from these organizations.
People without symptoms or taking low-dose Lipitor see minimal gains from CoQ10.
The label does not compare CoQ10 benefits by symptom status or Lipitor dose.
Contradictions
Important Omissions
For the discussion of muscle symptoms, the label advises patients to promptly report unexplained muscle pain, tenderness, or weakness, and says Lipitor should be discontinued if markedly elevated CPK occurs or myopathy is diagnosed or suspected.
Importance:
Moderate
The label does not establish that CoQ10 has no interaction with Lipitor; it identifies other agents that increase myopathy risk and recommends careful monitoring when specified combinations are used.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The claims give specific supplement dosing and reassurance about safety and lack of interaction that are not supported by the supplied label. The label also contains clinically relevant warnings about myopathy and rhabdomyolysis that should not be displaced by unsupported CoQ10 claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
Most CoQ10 efficacy, dosage, safety, and interaction claims are not supported by the supplied Lipitor prescribing information.
Suggested Improvement
Distinguish the label-supported Lipitor mechanism and muscle warnings from claims the label does not address, and avoid presenting CoQ10 dosing, efficacy, or interaction assurances as label-supported.